COMP <GO>
TKR vs TMO // FORWARD P/E MULTIPLE
Timken Company (The) (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: TKR 5
— TMO 10
▲ FORWARD P/E MULTIPLE LEADER: TKR
LAST: $110.90 (-3.42%) • MKT CAP: $7.96B
forward-pe
25.7x
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
forward-pe
36.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TKR VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | TKR | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.40% | 41.00% | -10.60 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.10% | 9.30% | -0.20 | TMO | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.2x | 30.4x | -17.20 | TKR | /valuation <GO> |
| Free Cash Flow Yield | 4.37% | 2.40% | +1.97 | TKR | /fcf-yield <GO> |
| Operating Margin | 11.80% | 17.40% | -5.60 | TMO | /operating-margins <GO> |
| Net Profit Margin | 6.30% | 15.10% | -8.80 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.20% | 3.90% | -3.70 | TMO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.24% | 0.24% | +1.00 | TKR | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.31 | 4.50 | -1.19 | TMO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 8/9 | -2.00 | TMO | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.70% | +0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 41.8 | 59.1 | -17.33 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.11 | 0.94 | +0.17 | TKR | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 25.7x | 36.3x | -10.60 | TKR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.96B | $262.22B | -$254.26B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | TKR REV | TMO REV | TKR GROSS % | TMO GROSS % | TKR FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $4.58B | $44.56B | 30.4% | 44.0% | $348.1M | $6.29B |
| FY 2024 | $4.57B | $42.88B | 31.5% | 44.0% | $269.9M | $7.27B |
| FY 2023 | $4.77B | $42.86B | 44.0% | 44.0% | $330.6M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TKR // BETA 1.11
TMO // BETA 0.94